136 related articles for article (PubMed ID: 8538482)
1. Postmenopausal osteoporosis: patient choices and outcomes.
Cosman F; Nieves J; Walliser J; Lindsay R
Maturitas; 1995 Sep; 22(2):137-43. PubMed ID: 8538482
[TBL] [Abstract][Full Text] [Related]
2. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Wimalawansa SJ
Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.
Cortet B; Béra-Louville A; Gauthier P; Gauthier A; Marchandise X; Delcambre B
Joint Bone Spine; 2001 Oct; 68(5):410-5. PubMed ID: 11707007
[TBL] [Abstract][Full Text] [Related]
4. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
Tiraş MB; Noyan V; Yildiz A; Biberoğlu K
Climacteric; 2000 Jun; 3(2):92-101. PubMed ID: 11910657
[TBL] [Abstract][Full Text] [Related]
5. Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study.
Gürlek A; Bayraktar M; Gedik O
Calcif Tissue Int; 1997 Jul; 61(1):39-43. PubMed ID: 9192511
[TBL] [Abstract][Full Text] [Related]
6. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
7. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
[TBL] [Abstract][Full Text] [Related]
8. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures.
Anderson FH; Francis RM; Bishop JC; Rawlings DJ
Age Ageing; 1997 Sep; 26(5):359-65. PubMed ID: 9351480
[TBL] [Abstract][Full Text] [Related]
9. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
Struys A; Snelder AA; Mulder H
Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
[TBL] [Abstract][Full Text] [Related]
10. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.
Miller PD; Watts NB; Licata AA; Harris ST; Genant HK; Wasnich RD; Ross PD; Jackson RD; Hoseyni MS; Schoenfeld SL; Valent DJ; Chesnut CH
Am J Med; 1997 Dec; 103(6):468-76. PubMed ID: 9428829
[TBL] [Abstract][Full Text] [Related]
11. Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis.
Crilly RG; Sebaldt RJ; Hodsman AB; Adachi JD; Brown JP; Goldsmith CH; Hanley DA; Olszynski WO; Ste-Marie LG; Stephenson GF
Osteoporos Int; 2000; 11(7):607-14. PubMed ID: 11069195
[TBL] [Abstract][Full Text] [Related]
12. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
Fogelman I; Herd RJ; Blake GM; Balena R
Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
[TBL] [Abstract][Full Text] [Related]
13. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
[TBL] [Abstract][Full Text] [Related]
14. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
Diamond T; McGuigan L; Barbagallo S; Bryant C
Am J Med; 1995 May; 98(5):459-63. PubMed ID: 7733124
[TBL] [Abstract][Full Text] [Related]
15. Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial.
Guañabens N; Farrerons J; Perez-Edo L; Monegal A; Renau A; Carbonell J; Roca M; Torra M; Pavesi M
Bone; 2000 Jul; 27(1):123-8. PubMed ID: 10865219
[TBL] [Abstract][Full Text] [Related]
16. Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation.
Orme SM; Simpson M; Stewart SP; Oldroyd B; Westmacott CF; Smith MA; Belchetz PE
Clin Endocrinol (Oxf); 1994 Aug; 41(2):245-50. PubMed ID: 7923830
[TBL] [Abstract][Full Text] [Related]
17. Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials.
Cardona JM; Pastor E
Osteoporos Int; 1997; 7(3):165-74. PubMed ID: 9205627
[TBL] [Abstract][Full Text] [Related]
18. Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women.
Bolanca S; Korsić M; Dekanić D; Cvijetić S
Acta Med Croatica; 1998; 52(3):159-63. PubMed ID: 9818438
[TBL] [Abstract][Full Text] [Related]
19. Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women.
Miller PD; Neal BJ; McIntyre DO; Yanover MJ; Anger MS; Kowalski L
Osteoporos Int; 1991 Jun; 1(3):171-6. PubMed ID: 1790405
[TBL] [Abstract][Full Text] [Related]
20. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
Holloway L; Kohlmeier L; Kent K; Marcus R
J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
